Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255453 | 1.00 | APP (0.33) | APPKDM4E | |
| SCHEMBL12217794 | 0.78 | APP (0.35) | APPKDM4E | |
| SCHEMBL25277802 | 0.78 | FOS (0.31) | — | |
| SCHEMBL335723 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL17966288 | 0.71 | TRPV4 (0.42) | — | |
| SCHEMBL1574430 | 0.71 | DYRK1A (0.32) | — | |
| SCHEMBL17966289 | 0.71 | TRPV4 (0.42) | — | |
| SCHEMBL1574432 | 0.71 | DYRK1A (0.32) | — | |
| SCHEMBL13639472 | 0.68 | TUBB4A (0.34) | APP | |
| SCHEMBL27832541 | 0.67 | PDK2 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2373657-B1 | 5,7-DIHYDRO-6H-PYRIMIDO[5,4-D][1]BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8507667-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507667-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120309743-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309743-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8268992-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998952-B2 | Thiolactams and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010065134-A1 | 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179126-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | APP 3448/4885KDM4E 1626/4885 |
| US-20110257157-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | APP 3448/4885KDM4E 1626/4885 |
| US-20150175542-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | APP 3448/4885KDM4E 1626/4885 |
| US-20140194410-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | APP 3448/4885KDM4E 1626/4885 |
| US-20120309743-A1 | THIOLACTAMS AND USES THEREOF | PLK3, PLK4, PLK2 | APP 3448/4885KDM4E 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.